Evidence map›Paper›PMID 35835183›Full record

ReviewExperimental eye research2022

Cell culture models to study retinal pigment epithelium-related pathogenesis in age-related macular degeneration.

Kapil Bharti, Anneke I den Hollander, Aparna Lakkaraju, Debasish Sinha, David S Williams, Silvia C Finnemann, Catherine Bowes-Rickman, Goldis Malek, Patricia A D'Amore

Open access · greenAbstract readReview
In one paragraph

Review in Experimental eye research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
15.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 79 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Mapping the Hypoxic Fitness Landscape of Retinal Pigment Epithelial Cells.International journal of molecular sciences · 2026
    Article
  11. Review
  12. Article
  13. QSAR Modeling for Predicting ICInternational journal of molecular sciences · 2025
    Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 2 countries.

Kapil BhartiOcular and Stem Cell Translational Research Section, National Eye Institute, NIH, Bethesda, MD, USA. Electronic address: kapil.bharti@nih.gov.
Anneke I den HollanderDepartment of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands; AbbVie, Genomics Research Center, Cambridge, MA, USA. Electronic address: anneke.denhollander@abbvie.com.
Aparna LakkarajuDepartment of Ophthalmology, School of Medicine, University of California, San Francisco, USA. Electronic address: Aparna.Lakkaraju@ucsf.edu.
Debasish SinhaDepartment of Ophthalmology, Cell Biology and Developmental Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: DEBASISH@pitt.edu.
David S WilliamsStein Eye Institute, Departments of Ophthalmology and Neurobiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: dswilliams@ucla.edu.
Silvia C FinnemannCenter of Cancer, Genetic Diseases, and Gene Regulation, Department of Biological Sciences, Fordham University, Bronx, NY, USA. Electronic address: finnemann@fordham.edu.
Catherine Bowes-RickmanDuke Eye Center, Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA; Department of Cell Biology, Duke University School of Medicine, Durham, NC, USA. Electronic address: bowes007@duke.edu.
Goldis MalekDuke Eye Center, Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA; Department of Pathology, Duke University School of Medicine, Durham, NC, USA. Electronic address: gmalek@duke.edu.
Patricia A D'AmoreMass Eye and Ear, Departments of Ophthalmology and Pathology, Harvard Medical School, Boston, MA, USA. Electronic address: patricia_damore@meei.harvard.edu.
Duke University · USFordham University · USJohns Hopkins University · USMassachusetts Eye and Ear Infirmary · USNational Eye Institute · USRadboud University Nijmegen · NLUniversity of California, Los Angeles · USUniversity of California, San Francisco · US

Funding

Developing patient-specific iPS cell derived RPE disease modelsZIAEY000532 · NEI · NATIONAL EYE INSTITUTE · PI BHARTI, KAPIL · 2013 to 2025
$22.0M
VISION RESEARCHP30EY005722 · NEI · DUKE UNIVERSITY · PI Goldis Malek · 1985 to 2026
$19.3M
Vision Research Core at UCLAP30EY000331 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DAVID S WILLIAMS · 1985 to 2026
$16.8M
Developing functional and authenticated RPE tissue from iPS cellsZIAEY000533 · NEI · NATIONAL EYE INSTITUTE · PI BHARTI, KAPIL · 2013 to 2025
$14.4M
Investigation of endomucin as a novel regulator of angiogenesisR01EY026539 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI D'AMORE, PATRICIA ANN · 2017 to 2024
$4.1M
Mechanisms of RPE dysfunction in macular degenerations: role of intracellular complement activationR01EY030668 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LAKKARAJU, APARNA · 2020 to 2024
$3.5M
Complement factor H modulates lipoprotein clearance in AMDR01EY031748 · NEI · DUKE UNIVERSITY · PI BOWES RICKMAN, CATHERINE · 2020 to 2024
$2.8M
RPE cell biology, aging, and diseaseR01EY027442 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WILLIAMS, DAVID S · 2017 to 2021
$2.6M
Targeting lysosome/RPE heterogeneity in AMD pathobiology as a novel therapyR01EY031594 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HANDA, JAMES T, SINHA, DEBASISH · 2021 to 2024
$2.4M
Molecular mechanisms of outer segment renewalR01EY026215 · NEI · FORDHAM UNIVERSITY · PI FINNEMANN, SILVIA C · 2016 to 2020
$2.0M
Nuclear receptor driven mechanisms in aging and AMDR01EY032751 · NEI · DUKE UNIVERSITY · PI MALEK, GOLDIS · 2021 to 2024
$1.8M
Regulation of inflammation and lipid homeostasis by the aryl hydrocarbon receptor in age-related macular degenerationR01EY028160 · NEI · DUKE UNIVERSITY · PI MALEK, GOLDIS · 2018 to 2021
$1.8M
Intramural NIH HHS ZIA EY000532NEI NIH HHS P30 EY000331NEI NIH HHS P30 EY005722NEI NIH HHS R01 EY026215NEI NIH HHS R01 EY026539NEI NIH HHS R01 EY027442NEI NIH HHS R01 EY028160NEI NIH HHS R01 EY030668NEI NIH HHS R01 EY031594NEI NIH HHS R01 EY031748NEI NIH HHS R01 EY032751NEI NIH HHS R21 EY031109
6 · The paper itself

Abstract

Age-related macular degeneration (AMD) is a disease that affects the macula - the central part of the retina. It is a leading cause of irreversible vision loss in the elderly. AMD onset is marked by the presence of lipid- and protein-rich extracellular deposits beneath the retinal pigment epithelium (RPE), a monolayer of polarized, pigmented epithelial cells located between the photoreceptors and the choroidal blood supply. Progression of AMD to the late nonexudative "dry" stage of AMD, also called geographic atrophy, is linked to progressive loss of areas of the RPE, photoreceptors, and underlying choriocapillaris leading to a severe decline in patients' vision. Differential susceptibility of macular RPE in AMD and the lack of an anatomical macula in most lab animal models has promoted the use of in vitro models of the RPE. In addition, the need for high throughput platforms to test potential therapies has driven the creation and characterization of in vitro model systems that recapitulate morphologic and functional abnormalities associated with human AMD. These models range from spontaneously formed cell line ARPE19, immortalized cell lines such as hTERT-RPE1, RPE-J, and D407, to primary human (fetal or adult) or animal (mouse and pig) RPE cells, and embryonic and induced pluripotent stem cell (iPSC) derived RPE. Hallmark RPE phenotypes, such as cobblestone morphology, pigmentation, and polarization, vary significantly betweendifferent models and culture conditions used in different labs, which would directly impact their usability for investigating different aspects of AMD biology. Here the AMD Disease Models task group of the Ryan Initiative for Macular Research (RIMR) provides a summary of several currently used in vitro RPE models, historical aspects of their development, RPE phenotypes that are attainable in these models, their ability to model different aspects of AMD pathophysiology, and pros/cons for their use in the RPE and AMD fields. In addition, due to the burgeoning use of iPSC derived RPE cells, the critical need for developing standards for differentiating and rigorously characterizing RPE cell appearance, morphology, and function are discussed.

Indexed as

Geographic AtrophyInduced Pluripotent Stem CellsMacular DegenerationAdultAgedAnimalsCell Culture TechniquesHumansMiceRetinal Pigment EpitheliumSwineARPE19Complement systemiPSC-RPEOrgan-on-a-ChipPrimary cellsRetinal pigment epithelium

Identifiers

PMID35835183
PMCPMC9444976
OpenAlexW4285023693

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.